Subirà O, Brosa H, Lorenzo-Parra D, Arias-Barquet L, Català-Mora J, Cobos E, Garcia-Bru P, Rubio-Caso M J, Caminal-Mitjana J M
Departamento de Oftalmología, Hospital Universitario de Bellvitge. , L'Hospitalet de Llobregat, Barcelona, España.
Departamento de Oftalmología, Hospital Universitario de Bellvitge. , L'Hospitalet de Llobregat, Barcelona, España.
Arch Soc Esp Oftalmol. 2017 Jun;92(6):257-264. doi: 10.1016/j.oftal.2016.11.013. Epub 2016 Dec 23.
To study the effectiveness and limitations of photodynamic therapy (PDT) as treatment of choice in patients with symptomatic circumscribed choroidal haemangioma.
A retrospective study was conducted on 16 patients (13 men and 3 women, with mean age of 54.88 years) with circumscribed choroidal haemangioma, who attended our centre and were treated with PDT in the last 7 years.
All patients had circumscribed choroidal haemangioma, which caused a decrease in visual acuity (VA) secondary to the presence of intraretinal microcystic oedema or neurosensory detachment. The mean initial VA was 0.23, and the final mean VA after performing PDT was 0.38 (all the VA were measured in decimal scale). It should be noted that patients needed a mean of 1.69 PDT sessions. Three of the patients needed rescue treatment with trans-pupillary thermotherapy, intravitreal injection of anti-vascular endothelial growth factor (ranibizumab, aflibercept) or a dexamethasone intravitreal implant (Ozurdex). The indication for a change of treatment was the persistence of intraretinal microcystic oedema and/or neurosensory detachment (or incomplete resolution) after 3 PDT sessions. As overall results, 62.5% of patients evolved into anatomical and functional (increase in AV or stability) resolution.
PDT is a straight forward and fast procedure, with a good anatomical and functional response, causing minimal damage to adjacent vessels.
研究光动力疗法(PDT)作为有症状的局限性脉络膜血管瘤患者首选治疗方法的有效性和局限性。
对16例局限性脉络膜血管瘤患者(13例男性,3例女性,平均年龄54.88岁)进行回顾性研究,这些患者在过去7年中就诊于本中心并接受了PDT治疗。
所有患者均患有局限性脉络膜血管瘤,由于存在视网膜内微囊性水肿或神经感觉脱离导致视力下降。初始平均视力为0.23,PDT治疗后的最终平均视力为0.38(所有视力均以小数记录法测量)。应当指出,患者平均需要1.69次PDT治疗。3例患者需要采用经瞳孔温热疗法、玻璃体内注射抗血管内皮生长因子(雷珠单抗、阿柏西普)或玻璃体内植入地塞米松(Ozurdex)进行挽救治疗。改变治疗方法的指征是在3次PDT治疗后视网膜内微囊性水肿和/或神经感觉脱离持续存在(或未完全消退)。总体结果显示,62.5%的患者在解剖学和功能上(视力提高或稳定)得到改善。
PDT是一种直接且快速的治疗方法,具有良好的解剖学和功能反应,对相邻血管造成的损伤最小。